Browse drugs

…slowing lung function decline in lcSSc. In addition, a trial of tofacitinib with 40 (61%) lcSSc patients showed that this drug was more eff…

…ow (see section on Current treatments). The antifibrotic drugs, pirfenidone and nintedanib, are established treatments for idiopathic pulmo…

…e primary outcome was the association between time to first AT (Adalimumab, Golimumab, Infliximab, Ustekinumab, Vedolizumab or Tofacitinib…

…factor inhibitors were ineffective or poorly tolerated, whereas tofacitinib and upadacitinib induced rapid and durable improvement across a…

…e Janus kinase inhibitors (JAKi), such as baricitinib (BAR) and tofacitinib (TOF), are oral therapeutic options for rheumatoid arthritis (R…

… two JAKi, and another 7% have received three. Drugs used were: upadacitinib (40%), baricitinib (35%), tofacitinib (24%), and filgotinib (11…

…n the STAT3 gene. Targeted therapy with Janus kinase inhibitor (tofacitinib) led to significant clinical and radiological improvement. This…

…s; tofacitinib (TOF), baricitinib (BAR), upadacitinib (UPA) and filgotinib (FIL)) in patients with rheumatoid arthritis (RA) in real-world…

… led to 43.2% clinical remission in an Emirati CD cohort, while tofacitinib achieved clinical remission rates of 56.4% and 61.1% at 52 week…

…29 children had significant IBD clinical symptoms when starting Ustekinumab. 16/20 (80%) saw some improvements at 3 months. At 6 months 8/2…